

Formulary Update

November 2024

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since September 2024. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Voxelotor	Sickle cell disease	9.1.8	Withdrawn from market

Additions	Indication	Adult Medicines Formulary entry/ rationale	
-----------	------------	--	--

Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Acetylcysteine	Acepiro is now the preferred brand; Nacsys is no longer a formulary choice.	3.7	Formulary change request
Lithium	Priadel highlighted as existing preferred brand in NHSGGC	4.2.3	Mental health team

Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Liraglutide	Highlighted ongoing supply issues with formulations used as appetite suppressant	4.5.2	Nationwide supply issue notification
Cystic fibrosis medicines	New sub-section created after NICE/SMC assessment and approval	3.12	SMC/NICE
Aripiprazole LAI	New prescribing note highlighting the 1-monthly long-acting injection is now available generically and is the formulary option in NHSGGC	4.2.2	Mental health team